Fotemustine
From Wikipedia, the free encyclopedia
-Fotemustine_Enantiomers_Structural_Formulae_V.1.svg) |
|
|---|---|
| Systematic (IUPAC) name | |
| (RS)-diethyl (1-{[(2-chloroethyl)(nitroso)carbamoyl]amino} ethyl)phosphonate |
|
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 92118-27-9 |
| ATC code | L01AD05 |
| PubChem | CID 104799 |
| DrugBank | EXPT03300 |
| ChemSpider | 94600  |
| UNII | GQ7JL9P5I2 |
| KEGG | D07255 |
| ChEMBL | CHEMBL549386 |
| Chemical data | |
| Formula | C9H19ClN3O5P |
| Mol. mass | 315.691 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
|
Fotemustine is a nitrosourea alkylating agent approved for use in the treatment of metastasising melanoma. A study[1] has shown that fotemustine produces improved response rates and increased survival over dacarbazine in the treatment of disseminated cutaneous melanoma.
[edit] External links
- ^ Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M (March 2004). Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study. 22. doi:10.1200/JCO.2004.04.165. PMID 15020614. http://jco.ascopubs.org/content/22/6/1118.full.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
